Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MOR 202

Drug Profile

MOR 202

Alternative Names: MOR-03087; MOR202; TJ-202

Latest Information Update: 01 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys
  • Developer I-MAB Biopharma; MorphoSys
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Phagocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma

Highest Development Phases

  • Phase III Multiple myeloma
  • Phase I/II Membranous glomerulonephritis
  • Preclinical Leukaemia
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 25 Oct 2019 Phase-I/II clinical trials in Membranous glomerulonephritis (Treatment-experienced) in France and Spain (IV) (EudraCT2019-000780-24)
  • 14 Oct 2019 National Medical Products Administration (NMPA) approves IND application for TJ202/MOR202 in Multiple myeloma in China
  • 29 Apr 2019 Phase-III clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in China (IV), Taiwan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top